文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

阿米替林治疗减轻脓毒症诱导的肿瘤坏死因子表达与凝血功能障碍

Amitriptyline Treatment Mitigates Sepsis-Induced Tumor Necrosis Factor Expression and Coagulopathy.
PubMed 文献 · Shock · 2019-01-01
一句话结论小鼠脓毒症模型中,阿米替林抑制巨噬细胞TNFα表达及M1极化,减轻早期高凝状态并防止迟发性低凝,作者认为是有前景的脓毒症相关凝血病治疗方向。

研究在盲肠结扎穿刺(CLP)小鼠脓毒症模型中观察阿米替林对炎症与凝血的影响。脓毒症小鼠早期出现高凝、后期出现低凝;阿米替林治疗组凝血指标与假手术组相似。脓毒症小鼠TNFα显著升高,阿米替林治疗组TNFα降低;向正常小鼠外源给予重组TNFα可复制脓毒症早期高凝表型。腹腔巨噬细胞是脓毒症及内毒素血症后TNFα的主要来源,阿米替林显著降低巨噬细胞TNFα表达并减弱M1极化。作者据此提出阿米替林是治疗脓毒症相关凝血病、预防急性血栓栓塞事件或迟发出血并发症的有前景方向。

要点

  • 在CLP小鼠脓毒症模型中,脓毒症小鼠表现为早期动态高凝、随后迟发性低凝,阿米替林治疗组凝血谱与假手术小鼠相似。
  • 脓毒症小鼠TNFα显著升高,阿米替林治疗组TNFα降低;正常小鼠外源给予重组TNFα可复制脓毒症急性高凝表型。
  • 脓毒症及内毒素血症后腹腔巨噬细胞是TNFα表达的主要来源,阿米替林显著降低巨噬细胞TNFα表达并减弱M1极化。
  • 作者认为阿米替林是治疗脓毒症相关凝血病、预防急性血栓栓塞事件或迟发出血并发症的有前景治疗方向。

适用人群与场景

  • 小鼠盲肠结扎穿刺(CLP)多微生物脓毒症模型;另在正常小鼠中给予重组TNFα复制脓毒症高凝表型。

处置流程与药物剂量

  • 阿米替林(AMIT)用于CLP脓毒症小鼠;原文未写明剂量、给药途径、频次或疗程。

研究设计与关键结果

  • 研究类型为小鼠脓毒症模型实验;脓毒症小鼠表现为早期动态高凝、随后迟发性低凝,阿米替林治疗组凝血谱与假手术小鼠相似。
  • 脓毒症小鼠TNFα显著升高,阿米替林治疗组TNFα降低;正常小鼠外源给予重组TNFα可复制脓毒症急性高凝表型。
  • 脓毒症及内毒素血症后腹腔巨噬细胞是TNFα表达的主要来源;阿米替林显著降低巨噬细胞TNFα表达并减弱M1极化。

证据类型、等级与局限

  • 证据类型:动物实验(小鼠CLP脓毒症模型);原文未报告证据等级或推荐强度。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为阿米替林是治疗脓毒症相关凝血病、预防急性血栓栓塞事件或迟发出血并发症的有前景治疗方向;该结论来自小鼠模型。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

During sepsis, the early innate response and inflammatory cytokine cascade are associated with activation of the coagulation cascade. Acute hypercoagulability can contribute to lethal sequela of vascular thrombosis, tissue ischemia, and organ failure. We investigated if amitriptyline (AMIT), an antidepressant drug with a number of anti-inflammatory effects, could ameliorate sepsis in a murine model of sepsis-cecal ligation and puncture (CLP). We hypothesized that AMIT treatment would reduce inflammation and mitigate sepsis-induced coagulopathy. Coagulation was measured using thromboelastometry and ferric chloride-induced carotid artery thrombosis. Our findings demonstrate a dynamic early hypercoagulability, followed by delayed hypocoagulability in septic mice. However, septic mice treated with AMIT were unaffected by these coagulation changes and exhibited a coagulation profile similar to sham mice. TNFα was markedly elevated in septic mice, but decreased in AMIT-treated mice. Exogenous administration of recombinant TNFα in naive mice recapitulated the acute sepsis-induced hypercoagulability profile. After sepsis and endotoxemia, peritoneal macrophages were the predominant source of TNFα expression. AMIT treatment significantly decreased macrophage TNFα expression and blunted M1 polarization. Altogether, during polymicrobial sepsis, AMIT treatment suppressed macrophage TNFα expression and the M1 phenotype, mitigating an initial hypercoagulable state, and protecting septic mice from delayed hypocoagulability. We propose that AMIT treatment is a promising therapeutic approach in the treatment of sepsis-associated coagulopathy and prevention of acute thromboembolic events or delayed bleeding complications.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Xia BT, Beckmann N, Winer LK, et al. Amitriptyline Treatment Mitigates Sepsis-Induced Tumor Necrosis Factor Expression and Coagulopathy. Shock. 2019. PMID: 29608550. doi:10.1097/SHK.0000000000001146

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。